Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases-Reference-Cited by-同舟云学术

Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases

Published:2020-05 Issue:14 Volume:16 Page:899-909
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Zimmer Alexandra S¹^ORCID,Steinberg Seth M²,Smart Dee Dee³,Gilbert Mark R⁴,Armstrong Terri S⁴,Burton Eric⁴,Houston Nicole¹,Biassou Nadia⁵,Gril Brunilde¹,Brastianos Priscilla K⁶,Carter Scott⁷,Lyden David⁸,Lipkowitz Stanley¹,Steeg Patricia S¹

Affiliation:

1. Women's Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA

2. Biostatistics & Data Management Section, National Cancer Institute, NIH, Bethesda, MD 20814, USA

3. Radiation Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA

4. Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA

5. Neuro-Radiology, Clinical Center, NIH, Bethesda, MD 20814, USA

6. Central Nervous System Metastases Program, Massachusetts General Hospital/Harvard Cancer Center Boston, MA 02114, USA

7. Biostatistics and Computation Biology, Dana-Farber Cancer Institute, Boston, MA 02114, USA

8. Pediatric Hematology Oncology, Weill Cornell Medicine, New York, NY 10065, USA

Abstract

Brain metastases occur in up to 25–55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood–brain barrier and is US FDA approved for treatment of glioblastoma. Our group has demonstrated that low doses of TMZ administered in a prophylactic, metronomic fashion can significantly prevent development of brain metastases in murine models of breast cancer. Based on these findings, we initiated a secondary-prevention clinical trial with oral TMZ given to HER2-positive breast cancer patients with brain metastases after recent local treatment in combination with T-DM1 for systemic control of disease. Primary end point is freedom from new brain metastases at 1 year. (NCT03190967).

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-0094

Reference70 articles.

1. Cancer statistics, 2019

2. Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System

3. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype

4. Metastatic Behavior of Breast Cancer Subtypes

5. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Distinct tumor architectures and microenvironments for the initiation of breast cancer metastasis in the brain;Cancer Cell;2024-09

2. Prevention of Brain Metastases: A New Frontier;Cancers;2024-06-04

3. Navigating breast cancer brain metastasis: Risk factors, prognostic indicators, and treatment perspectives;World Journal of Clinical Oncology;2024-05-24

4. Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer;Frontiers in Pharmacology;2024-01-30

5. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors;Journal of Hematology & Oncology;2024-01-04